Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women [1]

Thrombosis and Haemostasis

Volumn 94, Issue 3, 2005, Pages 682-683

  Vieira, Carolina S ^a   Ferriani, Rui A ^a   Garcia, Andréa A ^a   Gomes, Mariana K O ^a   Azevedo, George D ^b   Silva de Sá, Marcos Felipe ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; COLLAGEN; ETONOGESTREL; NONSTEROID ANTIINFLAMMATORY AGENT;

BLOOD SAMPLING; BODY MASS; CELL ASSAY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FOLLICULAR PHASE; HORMONAL CONTRACEPTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMPLANT; LETTER; LONGITUDINAL STUDY; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPECTROPHOTOMETRY; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

EID: 24944473168     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-03-0682     Document Type: Letter

References (13)

1. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-80.
2. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 131-4.
3. Singh K, Viegas OA, Koh SC et al. Effect of long term use of Norplant® implants on haemostatic function. Contraception 1992; 45: 203-19.
4. Singh K, Viegas OA, Koh SC et al. Effect of Norplant®-2 rods on haemostatic function. Contraception 1992; 45: 71-81.
5. Saleh AA, Ginsburg KA, Duchon TA et al. Hormonal contraception and platelet function. Thromb Res 1995; 78: 363-7.
6. Egberg N, van Beek A, Gunnervik C et al. Effects on hemostatic system and liver function in relation to Implanon® and Norplant®. A prospective randomized clinical trial. Contraception 1998; 58: 93-8.
7. Khetawat G, Faraday N, Nealen ML et al. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95: 2289-96.
8. Jayachandran M, Miller VM. Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets 2003; 14: 75-81.
9. Schindler AE, Campagnoli C, Druckmannc R et al. Classification and pharmacology of progestins. Maturitas 2003; 4651: S7-S16.
10. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol 1977; 232: 381-5.
11. Lindqvist PG, Rosing J, Malmquist A et al. Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system. J Thromb Haemost 2003; 1: 601-2.
12. Rosing J, Tans G, Nicolaes GA et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
13. Kemmeren JM, Algra A, Meijers JC et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 2004; 103: 927-33.